# US Atherosclerosis Market

> US Atherosclerosis Market Research Report: Size, Share, Trend Analysis By Stages (Endothelial Damage and Immune Response, Fatty Streak, Plaque Growth, Plaque Rupture), By Diagnosis (Ankle-brachial Index (ABI), Doppler Ultrasound, Echocardiogram, Electrocardiogram (ECG), Blood Tests, Others), By Treatment (Medication, Surgery) and By End-User (Hospitals, Specialty Clinics, Homecare, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.5%
- **2024:** $ 12.02 Billion
- **2025:** $ 12.44 Billion
- **2035:** $ 17.55 Billion
- **Key Players:** Pfizer Inc (US), AstraZeneca PLC (GB), Bristol-Myers Squibb Company (US), Novartis AG (CH), Sanofi S.A. (FR), Amgen Inc (US), Regeneron Pharmaceuticals Inc (US), Eli Lilly and Company (US)

**Report ID:** MRFR/MED/50446-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-atherosclerosis-market-52204

---

## Market Summary

## **US Atherosclerosis Market Overview**

As per MRFR analysis, the US Atherosclerosis Market Size was estimated at 9.95 (USD Billion) in 2023. The US Atherosclerosis Market Industry is expected to grow from 10.5 (USD Billion) in 2024 to 15.5 (USD Billion) by 2035.

The US Atherosclerosis Market CAGR (growth rate) is expected to be around 3.604% during the forecast period (2025 - 2035).

## **Key US Atherosclerosis Market Trends Highlighted**

The US Atherosclerosis Market has undergone noteworthy changes in the recent past due to the increasing occurrence of cardiovascular diseases. Cases of atherosclerosis are rising due to an aging population, lifestyle choices, and increasing rates of obesity. Improving heart health and cholesterol management awareness promoted by the Centers for Disease Control and Prevention (CDC) is empowering patients which result in more people seeking preventive care and treatment.

This shift towards prevention is increasing the need for new therapeutic products aimed at improving cholesterol and cardiovascular health. This market can be served more effectively with the use of new technologies, individualization, and personalized medicine. There is a focus on developing new therapies for specific patients which includes genetic profiling and other precision medicine approaches.

In addition to this, the growth of telemedicine and other digital health solutions during and after the COVID-19 pandemic allows easier consultation with healthcare providers which leads to better monitoring and adherence to treatment regimens. These strategies enable companies to better differentiate themselves by offering more tailored products. Recent trends have shown that even greater attention is being given to lifestyle treatment methods, like exercise and eating regimens, in the management of atherosclerosis.

Public health initiatives sponsored by government institutions motivate patients to improve their health habits, alongside the growing popularity of plant-rich diets and exercise programs. This method serves not only to tackle the condition at hand, but also enhances general health, subsequently driving the demand for goods and services in the US [Atherosclerosis Market](../../../reports/atherosclerosis-market-20668).

## **US Atherosclerosis Market Drivers**

### **Increasing Prevalence of Atherosclerosis in the US Population**

The US Atherosclerosis Market Industry is significantly driven by the rising prevalence of atherosclerosis among the population. As per the Center for Disease Control and Prevention (CDC), nearly 20% of adults aged 65 and older are diagnosed with heart disease, which includes atherosclerosis, translating into approximately 7 million affected individuals in the US. With the aging population and lifestyle changes, such as poor diet, lack of exercise, and obesity, this figure is projected to increase.

The National Institutes of Health (NIH) also underscores that the incidence of atherosclerotic cardiovascular disease is expected to rise due to demographic shifts and health trends. The growing number of individuals affected by atherosclerosis necessitates enhanced medical intervention and innovative treatment options, thus enhancing growth prospects within the US Atherosclerosis Market.

### **Advancements in Medical Technologies for Atherosclerosis Treatment**

Innovations in medical technology are a key driver for the US Atherosclerosis Market Industry. The adoption of minimally invasive procedures and advanced diagnostic tools contributes to better patient outcomes. For instance, the Food and Drug Administration (FDA) has approved several cutting-edge devices and therapies over the past few years. According to a report from the American College of Cardiology (ACC), there has been a notable increase in the use of catheter-based interventions, which have improved the management of atherosclerosis conditions.

Such advancements foster growth as healthcare providers seek effective solutions to treat atherosclerosis while ensuring patient comfort and satisfaction.

### **Growing Awareness and Education about Cardiovascular Diseases**

The increasing awareness and education surrounding cardiovascular diseases and atherosclerosis significantly impact the US Atherosclerosis Market Industry. The American Heart Association (AHA) has implemented numerous campaigns aimed at educating the public about heart health and the importance of managing risk factors such as cholesterol and blood pressure. According to the AHA, approximately 85.6 million Americans live with some form of cardiovascular disease, which has heightened the urgency for preventive measures.

Enhanced public knowledge can lead to early detection and treatment, ultimately driving the demand for atherosclerosis-related therapeutics and solutions in the US.

### **Government Initiatives and Funding for Atherosclerosis Research**

Government initiatives focused on the research and development of treatments for atherosclerosis serve as a crucial driver in the US Atherosclerosis Market Industry. The National Heart, Lung, and Blood Institute (NHLBI) provides substantial funding aimed at advancing atherosclerosis research and improving therapeutic options. In 2022 alone, the NHLBI invested millions into research programs targeting the understanding and treatment of cardiovascular diseases, including atherosclerosis.

This financial support enables the development of new pharmacological agents, interventions, and clinical trials, thereby enhancing treatment options and market growth potential in the US.

## **US Atherosclerosis Market Segment Insights**

### **Atherosclerosis Market Stages Insights**

The US Atherosclerosis Market has seen a nuanced segmentation concerning the different stages of the disease, each of which plays a pivotal role in determining health outcomes. The stages include Endothelial Damage and Immune Response, Fatty Streak, Plaque Growth, and Plaque Rupture, each contributing uniquely to the progression of atherosclerosis. Endothelial Damage and Immune Response marks the initial stage where the endothelium of blood vessels is compromised, often due to factors such as high cholesterol levels and inflammation.

This stage is crucial as it sets the foundation for subsequent developments. Fatty Streak follows as a response to the initial damage, highlighting the infiltration of lipids into the arterial walls and indicates early signs of atherosclerosis. It is essential to note that this stage is typically reversible if addressed with lifestyle changes. The third stage, Plaque Growth, signifies a more advanced development characterized by the accumulation of cells, lipids, and debris, which can threaten blood flow.

This stage often leads to cardiovascular diseases if not monitored or treated. Lastly, Plaque Rupture is a critical event that can precipitate acute clinical events like heart attacks or strokes, making it a focal point of therapeutic intervention. The importance of accurately identifying and managing these stages cannot be overstated as it directly correlates with improved patient outcomes and long-term management strategies.

Trends in the US indicate a growing awareness and proactive approach to atherosclerosis, driven largely by escalating rates of cardiovascular diseases. Furthermore, healthcare professionals are increasingly focusing on preventative measures and early diagnoses that target each of these stages, which is likely to shape future treatment protocols. As the population ages and lifestyle-related risk factors increase, the emphasis on understanding these stages and their implications within the framework of the US Atherosclerosis Market remains significant.

In summary, the stage-wise breakdown highlights vital areas for research and development efforts, as well as substantial opportunities for innovative therapies to mitigate the impact of atherosclerosis on public health. By understanding the pathophysiology inherent to each stage, stakeholders in the US Atherosclerosis Market can enhance their strategic focus, ultimately seeking to achieve better health outcomes and reduce the burden of cardiovascular diseases on the healthcare system.

### **Atherosclerosis Market Diagnosis Insights**

The Diagnosis segment of the US Atherosclerosis Market plays a pivotal role in the early detection and management of cardiovascular diseases, significantly impacting patient outcomes. Techniques like Ankle-brachial Index (ABI) and Doppler Ultrasound serve as vital non-invasive methodologies for assessing blood flow and arterial function, proving essential for preventative care strategies. The Echocardiogram and Electrocardiogram (ECG) are instrumental in evaluating heart functionality, allowing for timely interventions that can drastically alter disease progression.

Moreover, Blood Tests are crucial for identifying lipid profiles and inflammatory markers, enabling a comprehensive approach to risk assessment. Each diagnostic tool contributes uniquely to the broader landscape of cardiovascular health, with growing adoption driven by technological advancements and increased awareness of heart disease prevalence in the US. With rising healthcare initiatives focusing on preventive care, these diagnostic methods stand as cornerstones in managing atherosclerosis, ensuring continuous monitoring and timely treatment for affected individuals. Enhanced diagnostic accuracy and accessibility are further expected to stimulate market growth, reflecting the importance of these techniques in the healthcare ecosystem.

### **Atherosclerosis Market Treatment Insights**

The Treatment segment within the US Atherosclerosis Market focuses on addressing the challenges posed by this cardiovascular condition, which has significant implications for public health. With the market projected to experience steady growth, it encompasses various therapeutic approaches, predominantly Medication and Surgery. Medication is crucial as it establishes first-line defenses against lipid levels and inflammation, ensuring many patients manage their conditions effectively through lifestyle modifications combined with pharmaceutical interventions.

Meanwhile, Surgery plays a vital role for patients with advanced atherosclerosis, offering procedural options that can restore adequate blood flow and significantly reduce the risk of severe events like heart attacks. With the increasing prevalence of obesity and sedentary lifestyles in the US, the demand for both treatment modalities is likely to expand. Furthermore, healthcare reforms and advancements in medical technologies continue to drive growth in this sector, presenting opportunities for innovation in drug formulations and surgical techniques.

Overall, the Treatment segment remains a vital component in the fight against atherosclerosis, contributing to improved outcomes and quality of life for patients across the country.

### **Atherosclerosis Market End-User Insights**

The End-User segment of the US Atherosclerosis Market encompasses diverse healthcare settings where treatment and management of atherosclerosis take place. Hospitals dominate this segment, serving as primary facilities for acute care, advanced diagnostics, and specialized procedures, ensuring that patients receive timely intervention for cardiovascular conditions. Specialty Clinics also play a significant role, focusing on personalized treatment plans and preventive care tailored to individuals with atherosclerosis, thereby addressing specific patient needs effectively.

The Homecare sector is emerging as an important area, offering patients convenience and support in managing their condition within the comfort of their homes, which is increasingly favored by both patients and their families due to its potential for improved quality of life. Other settings related to patient care also contribute to the overall service framework, reflecting the various approaches taken to manage atherosclerosis effectively.

Market growth in this segment is driven by factors such as the rising prevalence of cardiovascular diseases, growing awareness of preventive healthcare, and advancements in treatment methodologies, presenting various opportunities for healthcare providers to innovate and improve patient outcomes. Additionally, challenges such as the need for efficient resource allocation and patient education remain pivotal in shaping future strategies in the management of atherosclerosis across these varied end-user settings.

## **US Atherosclerosis Market Key Players and Competitive Insights**

The US Atherosclerosis Market is characterized by a dynamic landscape where multiple players strive to gain a competitive edge by focusing on innovative solutions and advanced treatment options. This market is influenced by a rising prevalence of cardiovascular diseases, increasing awareness among healthcare providers regarding the importance of early diagnosis and management, and a growing emphasis on preventive healthcare measures. The competition in this sector spans several fronts, including the development of novel therapeutics, collaborations for research and development, and strategic marketing efforts to reach healthcare professionals and patients effectively.

As stakeholders in the healthcare ecosystem seek to enhance patient outcomes and reduce the burden of atherosclerosis, the strategies employed by market players shape a continuously evolving competitive scenario.

AstraZeneca has established a notable presence in the US Atherosclerosis Market, leveraging its strengths in research and development to innovate within the cardiovascular therapeutic segment. The company has invested significantly in clinical trials and partnerships, ensuring a robust pipeline of products that cater to various stages of atherosclerosis management. Its comprehensive approach towards patient care, supported by a focus on precision medicine, allows AstraZeneca to differentiate itself from other competitors.

With a long-standing commitment to advancing cardiovascular treatments, this company benefits from a wide distribution network and strong brand recognition that enhances its positioning and accessibility in the US healthcare landscape.

Takeda, a prominent player in the US Atherosclerosis Market, has established its foothold through a focus on delivering therapeutic solutions that align with unmet medical needs among patients affected by cardiovascular diseases. The company emphasizes its proprietary medications that target lipid management and associated risk factors, contributing to improved patient outcomes. With an active approach to mergers and acquisitions, Takeda has expanded its portfolio by incorporating cutting-edge therapies and strengthening its market presence. The company’s focus on innovative research, combined with strategic collaborations and alliances, amplifies its capabilities to drive growth in this competitive landscape.

By prioritizing patient health and safety, Takeda effectively aligns its goals with healthcare providers and patients, making a positive impact in the realm of atherosclerosis management.

### **Key Companies in the US Atherosclerosis Market Include**

## **US Atherosclerosis Market Industry Developments**

Recent developments in the US Atherosclerosis Market reveal significant advancements and competitive dynamics among major pharmaceutical companies such as AstraZeneca, Takeda, Merck, and Bristol Myers Squibb. In particular, AstraZeneca has made strides with its cardiovascular drug pipeline, targeting therapies that address inflammation linked to atherosclerosis. Meanwhile, Merck recently announced progress in its clinical trials for new atherosclerosis treatments, aiming to provide more effective options for patients.

Current market affairs include a notable increase in the valuation of several companies involved in Atherosclerosis treatment, attributed to heightened investment in Research and Development and a growing focus on preventative therapies. Additionally, among the notable merger and acquisition activities, in June 2023, Pfizer completed its acquisition of a biotech firm focused on cardiovascular drugs, indicating strategic consolidation within the sector.

Over the past few years, the market has seen heightened regulatory focus and scientific advancements, including a landmark approval in November 2022 for a new lipid-lowering therapy. Sanofi and Regeneron Pharmaceuticals continue to innovate with their cholesterol-lowering treatments, reflecting the increasing market competitiveness and focusing on reducing cardiovascular risks among the US population.

## **Atherosclerosis Market Segmentation Insights**

### **Atherosclerosis Market Stages Outlook**

### **Atherosclerosis Market Diagnosis Outlook**

### **Atherosclerosis Market Treatment Outlook**

### **Atherosclerosis Market End-User Outlook**

## Market Drivers

### Rising Healthcare Expenditure

The increasing healthcare expenditure in the US is a significant driver of the atherosclerosis market. As healthcare costs continue to rise, there is a growing emphasis on preventive care and effective management of chronic diseases, including atherosclerosis. In 2025, healthcare spending in the US is projected to exceed $4 trillion, reflecting a commitment to improving health outcomes. This financial investment is likely to enhance access to a range of treatment options, including medications, surgical interventions, and lifestyle modification programs. Furthermore, the focus on value-based care is encouraging healthcare providers to adopt comprehensive strategies for managing atherosclerosis, which may lead to increased demand for innovative therapies and interventions in the market.

### Advancements in Diagnostic Technologies

Technological innovations in diagnostic tools are significantly influencing the atherosclerosis market. Enhanced imaging techniques, such as high-resolution ultrasound and advanced MRI, allow for earlier detection and more accurate assessment of atherosclerotic plaques. These advancements facilitate timely intervention, which is crucial for improving patient outcomes. The US market for diagnostic imaging is projected to reach approximately $45 billion by 2026, indicating a robust demand for advanced diagnostic solutions. Furthermore, the integration of artificial intelligence in diagnostic processes is expected to streamline workflows and enhance accuracy. As healthcare providers increasingly adopt these technologies, the atherosclerosis market is likely to expand, driven by the need for precise diagnostics and personalized treatment plans.

### Regulatory Support for Innovative Therapies

Regulatory bodies in the US are increasingly supportive of innovative therapies for atherosclerosis, which is positively impacting the atherosclerosis market. The Food and Drug Administration (FDA) has implemented expedited review processes for breakthrough therapies, allowing for faster access to new treatments. This regulatory environment encourages pharmaceutical companies to invest in the development of novel therapies, knowing that they may receive quicker approval. The recent approval of several new drugs targeting atherosclerosis has demonstrated the potential for rapid market entry. As regulatory support continues to evolve, the atherosclerosis market is likely to benefit from an influx of innovative treatment options, ultimately improving patient care and outcomes.

### Growing Investment in Research and Development

Investment in research and development (R&D) is a critical driver of the atherosclerosis market. Pharmaceutical companies and research institutions are increasingly allocating resources to discover novel therapies and improve existing treatments. In the US, R&D spending in the healthcare sector has seen a steady increase, with estimates suggesting that it could reach $200 billion by 2025. This influx of funding is likely to accelerate the development of innovative drugs and therapies targeting atherosclerosis. Additionally, collaborations between academia and industry are fostering a conducive environment for breakthroughs in treatment modalities. As new therapies emerge, the atherosclerosis market is poised for growth, reflecting the commitment to addressing this pressing health issue.

### Increasing Prevalence of Cardiovascular Diseases

The rising incidence of cardiovascular diseases, particularly atherosclerosis, is a primary driver of the atherosclerosis market. In the US, approximately 697,000 individuals succumb to heart disease annually, highlighting the urgent need for effective treatment options. This alarming statistic underscores the necessity for innovative therapies and interventions. As the population ages, the prevalence of risk factors such as hypertension, diabetes, and obesity continues to escalate, further propelling the demand for atherosclerosis-related treatments. The atherosclerosis market is expected to witness substantial growth, with projections indicating a compound annual growth rate (CAGR) of around 5.5% over the next several years. This trend suggests that healthcare providers and pharmaceutical companies must prioritize the development of new therapies to address the increasing burden of cardiovascular diseases.

## Future Outlook

The [Atherosclerosis Market](https://www.marketresearchfuture.com/reports/atherosclerosis-market-20668) is projected to grow at a 3.5% CAGR from 2025 to 2035, driven by advancements in treatment options, increasing prevalence, and heightened awareness.

**New opportunities:**

- Development of telehealth platforms for remote patient monitoring Investment in AI-driven diagnostic tools for early detection Expansion of personalized medicine approaches targeting specific patient demographics

By 2035, the atherosclerosis market is expected to achieve substantial growth, reflecting evolving healthcare dynamics.

## Segment Insights

### By Stage: Plaque Rupture (Largest) vs. Endothelial Damage and Immune Response (Fastest-Growing)

In the US atherosclerosis market, the segment distribution shows that Plaque Rupture holds the largest share, reflecting the critical impact of this phase on patient outcomes and treatment strategies. Following closely, the Endothelial Damage and Immune Response segment is gaining traction due to increasing awareness of early intervention and its significance in preventing the progression to more severe stages.

Growth trends in the segment indicate a shift toward more preventive measures, with healthcare providers focusing on addressing endothelial damage as a pivotal step in atherosclerosis management. The rapid growth in the Endothelial Damage and Immune Response sector is driven by advancements in diagnostic technologies and the evolving understanding of immune mechanisms affecting atherosclerosis, promoting innovative therapeutic strategies to mitigate risks early in the disease process.

Plaque Rupture (Dominant) vs. Fatty Streak (Emerging)

Plaque Rupture is recognized as the dominant stage within the US atherosclerosis market due to its direct association with acute cardiovascular events, leading to extensive clinical attention and resource allocation. Its established presence is supported by ongoing research and development aimed at finding effective interventions to manage complications. In contrast, the Fatty Streak stage is emerging as an important focus for early intervention strategies. As clinicians increasingly acknowledge the need to address the initial stages of atherosclerosis, the Fatty Streak segment is gaining visibility. This increasing attention reflects a broader trend towards proactive healthcare models that emphasize early diagnosis and lifestyle modifications to slow disease progression.

### By Diagnosis: Blood Tests (Largest) vs. Ankle-brachial Index (ABI) (Fastest-Growing)

In the US atherosclerosis market, Blood Tests hold the largest market share, attributed to their widespread use and efficiency in diagnosing a range of cardiovascular conditions. The popularity of Blood Tests stems from their ability to provide crucial insights into cholesterol levels and other biomarkers, making them a preferred choice among healthcare providers. Following closely are methods like Doppler Ultrasound and Electrocardiogram (ECG), but they account for a smaller share of the market.

The growth trends within this segment indicate a rising demand for non-invasive diagnostic tools such as the Ankle-brachial Index (ABI), which is currently the fastest-growing method. This trend is driven by increasing awareness of atherosclerosis and the need for early detection. Additionally, technological advancements in ultrasound and the development of more sophisticated blood tests are fueling expansion in this sector, as practitioners seek reliable and efficient diagnostic options.

Blood Tests (Dominant) vs. Ankle-brachial Index (ABI) (Emerging)

Blood Tests are a dominant force in the diagnostic landscape of the US atherosclerosis market, providing essential data for the assessment of lipid profiles and inflammatory markers. Their non-invasive nature and ability to conduct multiple tests from a single sample makes them highly valued among clinicians. Conversely, the Ankle-brachial Index (ABI) is an emerging diagnostic tool that measures the blood flow in limbs and assists in identifying peripheral arterial diseases. The ABI’s rise in favor is linked to its efficiency and accuracy in identifying at-risk patients, making it a vital asset in preventive healthcare strategies. As healthcare systems continue to emphasize early intervention, the ABI is rapidly gaining traction, complementing traditional blood tests.

### By Treatment: Medication (Largest) vs. Surgery (Fastest-Growing)

In the US atherosclerosis market, the treatment segment is primarily dominated by medication, which holds the largest market share. Medication comprises various pharmaceutical products aimed at managing cholesterol levels and improving cardiovascular health. In contrast, surgery is emerging as a significant option for patients requiring more immediate intervention, contributing to its rapid growth. The distinct approaches of both treatment methods cater to varying patient needs, establishing a clear market hierarchy where medication is currently the preferred choice among healthcare providers.

The growth trends within the treatment segment highlight a shift in patient management strategies, with an increasing emphasis on surgical interventions for those with severe atherosclerosis. Advancements in minimally invasive techniques and surgical technologies are propelling the surgery segment forward, making it faster-growing. Furthermore, rising awareness and education about atherosclerosis management among patients and healthcare professionals are driving demand for these treatment options, thus shaping the future landscape of the treatment segment.

Treatment: Medication (Dominant) vs. Surgery (Emerging)

Medication is the dominant treatment in the US atherosclerosis market, leveraging a wide range of drugs that effectively lower cholesterol levels and prevent cardiovascular events. It is characterized by its accessibility and the extensive clinical research supporting its efficacy. Patients often favor medication due to the non-invasive nature and ease of administration. On the other hand, surgery is an emerging option that is becoming more prevalent, especially in cases where medication alone proves inadequate. Surgical interventions, including angioplasty and bypass procedures, are gaining traction owing to advancements in techniques and increased success rates. As healthcare professionals look for proactive measures, surgery is anticipated to capture more of the market, reflecting a balance of traditional management with innovative surgical solutions.

### By End-User: Hospitals (Largest) vs. Specialty Clinics (Fastest-Growing)

In the US atherosclerosis market, the distribution of the end-user segment reveals that hospitals hold the largest share, demonstrating their critical role in patient care. These institutions provide advanced diagnostic and therapeutic solutions for managing atherosclerosis, accounting for a significant portion of the market revenue. Specialty clinics, on the other hand, are rapidly gaining traction due to their focused approach and specialized treatments, making them the fastest-growing segment in the market. 

Growth trends in this segment are driven by the increasing prevalence of cardiovascular diseases, leading to heightened demand for targeted care. The rise in preventive healthcare and advancements in medical technology further stimulate the expansion of specialty clinics, as they offer innovative solutions tailored to individual patient needs. This dynamic environment fosters competition among hospitals and specialty clinics, enhancing service delivery and patient outcomes.

Hospitals (Dominant) vs. Specialty Clinics (Emerging)

Hospitals represent the dominant end-user segment in the US atherosclerosis market, characterized by their comprehensive capabilities in managing complex cases of atherosclerosis. They provide access to multidisciplinary teams and state-of-the-art technologies, ensuring that patients receive holistic care. Conversely, specialty clinics are emerging as a significant player, focusing on specific patient demographics and offering personalized treatment plans. These clinics emphasize convenience and accessibility, appealing to patients seeking quicker consultations and specialized care. With their agility and focus, specialty clinics are carving out a niche in the market, driven by a demand for tailored healthcare solutions and an increasing awareness of preventative cardiovascular care.

## Competitive Benchmarking

The atherosclerosis market exhibits a dynamic competitive landscape characterized by rapid innovation and strategic maneuvering among key players. Major companies such as Pfizer Inc (US), AstraZeneca PLC (GB), and Amgen Inc (US) are actively engaged in enhancing their product portfolios and expanding their market presence. Pfizer Inc (US) has focused on developing novel therapies aimed at reducing cardiovascular risk, while AstraZeneca PLC (GB) emphasizes its commitment to research and development, particularly in the realm of lipid management. Amgen Inc (US) is leveraging its expertise in biologics to introduce advanced treatment options, thereby positioning itself as a leader in the market. Collectively, these strategies foster a competitive environment that prioritizes innovation and patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the atherosclerosis market appears moderately fragmented, with several players vying for market share. However, the influence of key players is substantial, as they drive advancements in treatment options and establish benchmarks for quality and efficacy.
In October Bristol-Myers Squibb Company (US) announced a strategic partnership with a leading digital health firm to integrate AI-driven analytics into its clinical development processes. This move is likely to enhance the company's ability to identify patient populations that would benefit most from its therapies, thereby streamlining clinical trials and accelerating time-to-market for new treatments. Such initiatives underscore the growing importance of technology in shaping drug development and patient engagement strategies.
In September Regeneron Pharmaceuticals Inc (US) launched a new initiative aimed at expanding access to its atherosclerosis treatments through collaborations with healthcare providers and payers. This initiative is expected to improve patient outcomes by ensuring that innovative therapies are accessible to a broader demographic, particularly underserved populations. The strategic focus on access aligns with current healthcare trends emphasizing equity and inclusivity in treatment availability.
In August Novartis AG (CH) unveiled a comprehensive sustainability strategy that includes commitments to reduce its carbon footprint and enhance the environmental profile of its manufacturing processes. This initiative not only addresses growing regulatory pressures but also resonates with the increasing consumer demand for sustainable practices in healthcare. By prioritizing sustainability, Novartis AG (CH) positions itself favorably in a market that is progressively valuing corporate responsibility.
As of November the atherosclerosis market is witnessing trends that emphasize digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming increasingly pivotal, as companies collaborate to enhance their capabilities and expand their reach. The competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that can effectively leverage these trends will be better positioned to thrive in the evolving landscape.

## Recent News & Developments

Recent developments in the US Atherosclerosis Market reveal significant advancements and competitive dynamics among major pharmaceutical companies such as AstraZeneca, Takeda, Merck, and Bristol Myers Squibb. In particular, AstraZeneca has made strides with its cardiovascular drug pipeline, targeting therapies that address inflammation linked to atherosclerosis. Meanwhile, Merck recently announced progress in its clinical trials for new atherosclerosis treatments, aiming to provide more effective options for patients.

Current market affairs include a notable increase in the valuation of several companies involved in Atherosclerosis treatment, attributed to heightened investment in Research and Development and a growing focus on preventative therapies. Additionally, among the notable merger and acquisition activities, in June 2023, Pfizer completed its acquisition of a biotech firm focused on cardiovascular drugs, indicating strategic consolidation within the sector.

Over the past few years, the market has seen heightened regulatory focus and scientific advancements, including a landmark approval in November 2022 for a new lipid-lowering therapy. Sanofi and Regeneron Pharmaceuticals continue to innovate with their cholesterol-lowering treatments, reflecting the increasing market competitiveness and focusing on reducing cardiovascular risks among the US population.

## Report Scope

| MARKET SIZE 2024 | 12.02(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 12.44(USD Billion) |
| MARKET SIZE 2035 | 17.55(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.5% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Pfizer Inc (US), AstraZeneca PLC (GB), Bristol-Myers Squibb Company (US), Novartis AG (CH), Sanofi S.A. (FR), Amgen Inc (US), Regeneron Pharmaceuticals Inc (US), Eli Lilly and Company (US) |
| Segments Covered | Stage, Diagnosis, Treatment, End-User |
| Key Market Opportunities | Advancements in personalized medicine and digital health technologies enhance treatment options in the atherosclerosis market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the atherosclerosis treatment landscape. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US atherosclerosis market in 2024?**
A: The overall market valuation was $12.02 Billion in 2024.

**Q: What is the projected market valuation for the US atherosclerosis market by 2035?**
A: The projected valuation for 2035 is $17.55 Billion.

**Q: What is the expected CAGR for the US atherosclerosis market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during this period is 3.5%.

**Q: Which companies are considered key players in the US atherosclerosis market?**
A: Key players include Pfizer Inc, AstraZeneca PLC, Bristol-Myers Squibb Company, Novartis AG, Sanofi S.A., Amgen Inc, Regeneron Pharmaceuticals Inc, and Eli Lilly and Company.

**Q: What are the segment valuations for the treatment of atherosclerosis in 2024?**
A: In 2024, the treatment segment was valued at $8.02 Billion for medication and $4.0 Billion for surgery.

**Q: How did the valuation of the 'Plaque Growth' stage segment change from 2024 to 2025?**
A: The 'Plaque Growth' stage segment increased from $3.5 Billion in 2024 to a projected $5.0 Billion in 2025.

**Q: What is the valuation of the 'Blood Tests' diagnostic segment in 2024?**
A: The 'Blood Tests' diagnostic segment was valued at $3.0 Billion in 2024.

**Q: What are the projected values for the 'Doppler Ultrasound' diagnostic segment by 2035?**
A: The projected value for the 'Doppler Ultrasound' diagnostic segment is $3.5 Billion by 2035.

**Q: What is the expected growth in the 'End-User' segment for hospitals from 2024 to 2035?**
A: The 'End-User' segment for hospitals is expected to grow from $4.81 Billion in 2024 to $6.93 Billion by 2035.

**Q: How does the market for atherosclerosis treatments compare between medication and surgery in 2024?**
A: In 2024, the market for atherosclerosis treatments was $8.02 Billion for medication and $4.0 Billion for surgery.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-atherosclerosis-market-52204*